Travere Therapeutics-Travere licenses Everest's kidney disease drug in deal worth up to $1.14 billion

Travere licenses Everest's kidney disease drug in deal worth up to $1.14 billion

公司合作与交易 - Travere Therapeutics与私人控股的生物技术公司Everest Medicines签署了一项许可协议，共同开发和商业化一种实验性肾病药物 [1] - 该交易的总价值最高可达... [1]

Travere Therapeutics-Travere licenses Everest's kidney disease drug in deal worth up to $1.14 billion - Reportify